842 results on '"Fujii, Masashi"'
Search Results
2. Correction: Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study
3. The low-temperature thermal conduction and millimeter-wave dielectric properties of β-Si3N4 as a heat-dissipation substrate
4. Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study
5. Pulsus bisferiens and volume resuscitation
6. Self-Organization of Diverse Directional Hierarchical Networks in Simple Coupled Maps with Connection Changes
7. A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09)
8. Spontaneous organizations of diverse network structures in coupled logistic maps with a delayed connection change
9. Human epidermal growth factor 2 overexpressed alpha-fetoprotein-producing-gastric cancer
10. Energy-saving in fucoxanthin production by Chaetoceros gracilis in a flat-bag photobioreactor with intermittent mixing
11. Robustness against additional noise in cellular information transmission
12. Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial
13. Development of hydrogen ionic plasma source with superimposed positive-ion beam.
14. Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07
15. Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08)
16. In vivo transomic analyses of glucose-responsive metabolism in skeletal muscle reveal core differences between the healthy and obese states
17. Four features of temporal patterns characterize similarity among individuals and molecules by glucose ingestion in humans
18. Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial
19. Characteristic imaging findings of tendinosis of the direct head of rectus femoris and their interpretation
20. 18F-FDG-PET/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer (JACCRO CC-12)
21. Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09
22. Small-volume effect enables the spine robust, sensitive and efficient information transfer
23. Effect of wearing a surgical mask on short-term pulmonary gas exchange in patients immediately after anaesthesia
24. Trans-omic analysis reveals obesity-associated dysregulation of inter-organ metabolic cycles between the liver and skeletal muscle
25. Preoperative medications is one of the factor affecting patient-reported outcomes after total hip arthroplasty
26. Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08).
27. The location of the fracture determines the better solution, osteosynthesis or revision, in periprosthetic femoral fractures
28. Trans-omic Analysis Reveals ROS-Dependent Pentose Phosphate Pathway Activation after High-Frequency Electrical Stimulation in C2C12 Myotubes
29. Single-Cell Information Analysis Reveals That Skeletal Muscles Incorporate Cell-to-Cell Variability as Information Not Noise
30. Ultrasensitive Change in Nucleosome Binding by Multiple Phosphorylations to the Intrinsically Disordered Region of the Histone Chaperone FACT
31. A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).
32. Genome-wide DNA methylation status to predict the efficacy of modified (m)-FOLFOXIRI plus cetuximab as initial treatment for RAS wild-type metastatic colorectal cancer: A biomarker study of the DEEPER trial (JACCRO CC-13AR).
33. Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08
34. Monitoring and mathematical modeling of mitochondrial ATP in myotubes at single-cell level reveals two distinct population with different kinetics
35. Stochasticity in Ca$^{2+}$ increase in spines enables robust and sensitive information coding
36. Factors influencing the injury severity score and the probability of survival in patients who fell from height
37. Effects of teriparatide on bone in autochthonous transgenic model mice for diabetes mellitus (Akita mice)
38. NMDAR-Mediated Ca2+ Increase Shows Robust Information Transfer in Dendritic Spines
39. Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial)
40. Influences of Excluded Volume of Molecules on Signaling Processes on Biomembrane
41. Segregation pattern reorientation of granular mixture on horizontally oscillating tray
42. Saddle-Node Bifurcation to Jammed State for Quasi-One-Dimensional Counter Chemotactic Flow
43. Counter Chemotactic Flow in Quasi-One-Dimensional Path
44. Correlation of multiple endpoints in the first‐line chemotherapy of advanced gastric cancer: Pooled analysis of individual patient data from Japanese Phase III trials
45. Factors Affecting the Second Complete Atypical Femoral Fracture after the First Atypical Fracture
46. 10150-GGE-16 INTRAOPERATIVE INTEGRATED DIAGNOSTIC SYSTEM FOR MALIGNANT CENTRAL NERVOUS SYSTEM TUMORS
47. Characteristics and Treatment Strategies for Basicervical and Transcervical Shear Fractures of the Femoral Neck
48. MO18-4 RAS status in ctDNA and efficacy of FOLFIRI plus ramucirumab in 2nd-line therapy for RAS wild-type mCRC: JACCRO CC-16AR
49. O4-3 An update analysis of the JACCRO CC-16: Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to anti-EGFR antibody
50. PS4-3 Survival analysis of m-FOLFOXIRI plus cetuximab vs. bevacizumab in RAS wild-type mCRC: The DEEPER trial (JACCRO CC-13)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.